Gray Hair Is Not a Disease. FTC Sued Anyway.

what did the three catalase companies actually claim in their ads?

All three companies sold the same mechanism story under different brand names: a catalase-enzyme pill said to neutralize the hydrogen peroxide that supposedly builds up in aging hair follicles and turns hair gray. GetAwayGrey LLC, Rise-N-Shine LLC's "Go Away Gray," and COORGA Nutraceuticals Corp.'s "Grey Defence" all promised two pills a day would undo graying already visible in the mirror, and FTC's May 2015 complaints reproduced the line word for word: "Just two vitamin pills a day can bring back your natural hair color."

COORGA went further, quantifying the result.

Grey Defence's ads didn't stop at a mechanism story; they cited a customer survey claiming most users saw their gray reverse, turning an unverified in-house poll into a specific, share-worthy percentage. All three products retailed for $29.95 to $69.99 and moved through CVS and Walgreens, not fringe mail-order catalogs, which is part of why the FTC treated the claims as mainstream consumer harm rather than a niche problem.

why did the ftc act when no disease claim was involved?

The FTC acted because gray hair never had to clear FDA's disease line to trigger liability. Section 5 of the FTC Act bars any deceptive or unsubstantiated efficacy claim, whether or not the underlying condition qualifies as a disease under 21 CFR 101.93(g), FDA's test for when a claim counts as disease treatment. Reversing pigment loss is a physical-effect claim like any other, and the FTC Health Products Compliance Guidance sets randomized, controlled human clinical testing as the general standard for substantiating that kind of claim. Catalase's producers had no such trial behind the reversal number they printed on the label.

That's the whole point of this case for anyone building on FDA-safe territory.

We checked whether either complaint alleged a disease claim alongside the cosmetic one, since that's the more familiar enforcement path — there isn't one in either case. The theory was pure substantiation failure: a claim that a product changes a physical characteristic needs competent and reliable evidence, full stop, independent of whether FDA would ever look at it.

what happened to the company's own observational study in court?

The court threw it out entirely. On September 23, 2016 the U.S. District Court for the District of Wyoming granted the FTC summary judgment against COORGA Nutraceuticals and Garfield Coore, entering a $391,335 judgment, and found that "a customer survey the defendants conducted was not well-designed or scientifically controlled." The 65% reversal figure Grey Defence had advertised as an observational study was, in the court's own words, not a controlled study at all.

Summary judgment means the case never reached a jury.

The distinction matters for anyone leaning on a customer poll or an in-house write-up dressed up as research: an uncontrolled survey run by the seller fails FTC's evidentiary bar before it even reaches the randomized-trial question, the same self-serving-evidence pattern that shows up in Fake Amazon Reviews: FTC's First Supplement Case.

how did the owner end up personally liable for the copy?

Garfield Coore was held personally liable because the court found he ran the company, not just owned it. The same 2016 Wyoming ruling that rejected COORGA's survey found Coore had personally supervised and directed every aspect of the business, and had either known the claims were false or been recklessly indifferent to whether they were.

Personal liability under the FTC Act doesn't require proof of intent to defraud. Recklessness about the truth of your own copy is enough, and corporate structure offers no shield once a court finds an individual controlled the messaging — the same theory that runs through The Neuropathy Case That Ended a Supplement Company.

You can't outsource the copy and keep the liability separate.

what evidence would have counted as substantiation instead?

One randomized, controlled human clinical trial on the actual product — not a customer poll, not animal data, not a testimonial roundup — would have been the floor. FTC's compliance guidance treats trial evidence as the standard for any claim that a product changes a measurable physical outcome, and gray-hair reversal fits that description exactly: it's testable, it's binary (hair color changed or it didn't), and it doesn't need decades of follow-up to measure.

None of the three companies had one.

A well-controlled trial would need a placebo arm, blinded assessment of hair-color change, a defined study population, and a reported effect size — not a rounded percentage pulled from a self-administered questionnaire. We could not verify whether any of the three companies ever commissioned such a trial after settling; that would need checking against FTC's compliance-monitoring record before assuming the door is closed on catalase products for good.

how far can an ftc remedy reach beyond the single product?

An FTC remedy can reach far beyond the specific product that triggered the case, right down to closing an entire industry to the defendant. The 1998 settlement with infomercial marketer Jacqueline Sabal over the "Sable Hair Farming System" included, according to Commissioner Swindle's published statement, "a ban on participating in any business involving hair loss prevention, hair growth, or baldness treatments" — not a fine tied to Sable's revenue, an industry-wide exit.

That's a category-wide exit, not a product recall.

The catalase cases stayed monetary rather than injunctive, but the structure is the one broken down in $3.5M in Refunds at $33 a Check: The Redress Math: a judgment sized to deter, with most of it suspended so long as the defendant surrenders the assets already on record.

what does this mean for offers built on a cosmetic, non-disease promise?

Clearing FDA's disease line buys an advertiser nothing at the FTC, and that's the single most important carryover from this case to any cosmetic-appearance offer: wrinkles, hair color, skin tone, nail shine, anything the law treats as normal cosmetic aging rather than disease. Gray hair sailed straight through 21 CFR 101.93(g) without triggering a single disease-claim criterion: it isn't a symptom of illness, it doesn't convey disease through the product name, and nobody needs a diagnosis to notice it. None of that mattered once the ads promised a specific, testable physical change with no trial behind the number. We changed our mind, working through this case, about which line actually determines liability here — it isn't FDA's, it's FTC's, and the two questions have almost nothing to do with each other.

Your compliance checklist needs both boxes checked, not one.

If your product claims to change a visible, measurable trait — color, texture, count, size — you're making an efficacy claim FTC will hold to its competent-and-reliable-evidence standard, regardless of what FDA thinks about the underlying condition. Testimonials, customer surveys and self-run observational studies are not a substitute; the Wyoming court already showed what happens to that kind of evidence once it reaches a judge.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, How Much Does It Cost to Private Label Supplements?, Health & Fitness Affiliate Marketing: Nutra Vertical Guide for Sellers and Affiliates, Case Study: Nutra Conversion with Push Ads from Richads, Menopause Supplement Lebanon: What Matters and What Does Not, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.